Novartis has settled a lawsuit brought by Daiichi Sankyo’s Plexxikon subsidiary, paying $180 million to resolve claims that its Tafinlar cancer drug infringed US patents h
Novartis' two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E mutation – regardless of where they occur in t
Eli Lilly has added $1 billion to its investment plan for a new manufacturing facility in Ireland that will be used to produce its Alzheimer's therapy donanemab.
The Life Sciences Generative AI Council aims to bring together the best minds in pharma, academia, and technology to advance the use of GenAI in life sciences R&D, seeking through pinpo